| Drug Name |
Dasatinib |
| Drug ID |
BADD_D00589 |
| Description |
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR. |
| Indications and Usage |
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. |
| Marketing Status |
Prescription |
| ATC Code |
L01EA02 |
| DrugBank ID |
DB01254
|
| KEGG ID |
D03658
|
| MeSH ID |
D000069439
|
| PubChem ID |
3062316
|
| TTD Drug ID |
D0E6XR
|
| NDC Product Code |
63285-862; 63285-867; 0003-0855; 63285-863; 63285-866; 63285-865; 68554-0070; 54893-0015; 54893-0047; 0003-0857; 0003-0852; 0003-0527; 0003-0528; 76302-014; 50193-0524; 46708-891; 14778-1313; 62207-973; 63285-864; 0003-0524; 59651-468; 53104-7725 |
| Synonyms |
Dasatinib | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | Sprycel | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | BMS 354825 | 354825, BMS | BMS354825 | BMS-354825 |
